Tag archive for ‘Erez Vigodman’
Albert Hecht On Monday, September 11th, 2017

New Teva CEO Kare Schultz Grants $20 Million in Cash, $13.5 Million in Securities

New Teva CEO Kare Schultz will earn an annual salary of $2 million and a performance-dependent bonus of 140% of the base salary – and up to a maximum of 200%. The Israeli Teva Pharmaceutical Industries has More...

Jewish Business News On Tuesday, February 7th, 2017

Teva CEO Erez Vigodman Unexpectedly Resigns Effective Immediately

Teva : L-R Erez Vinograd, Yitzhak Peterburg Israeli generic drugmaker Teva Pharmaceutical Industries Ltd announced last night that Teva CEO Erez Vigodman has resigned effective immediately. The company said it More...

Shiri Habib-Valdhorn On Monday, July 27th, 2015

Three Way Takeover Battle – The End: Teva Losing $300 Million on Mylan Stake

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has officially announced that it is withdrawing its bid to buy generic pharmaceuticals rival Mylan N.V. after agreeing to buy Allergan Generics More...

Niva Goldberg On Thursday, July 16th, 2015

Mylan Battles Against Teva Takeover: US Consumer Groups Oppose Merger

“A takeover of Mylan by Teva is a bad deal for consumers, ” claim. US consumer organizations that have jointly written to the Federal Trade Commission (FTC) demanding that it block the Teva-Mylan More...

Niva Goldberg On Tuesday, July 7th, 2015

Three Way Takeover Battle: Teva Plans Raising Mylan Bid to $43 Billion – Report

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), the Israeli drugmaker, is preparing to improved proposal for US rival Mylan to as much as $43 billion, $86 to $88 a share, as soon as this More...

Shiri Habib-Valdhorn On Wednesday, July 1st, 2015

Teva CEO: The Industry Is Undergoing a Shakeup

“Size is important in the industry, but it isn’t everything. It’s important to be better. You have to make acquisitions that will suit the company’s strategic direction and contribute More...

Three Way Takeover Battle: Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced on Friday that it has completed the purchase of a 4.61% More...

Shiri Habib-Valdhorn On Thursday, June 18th, 2015

Three Way Takeover Battle: Teva’s Mylan Stake Up to 4.3%

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) continues to accumulate shares in takeover target Mylan (MYL), even as Mylan’s largest shareholder, Abbott Labs (NYSE: ABT), announced More...

Shiri Habib-Valdhorn On Monday, June 15th, 2015

Three Way Takeover Battle: Statistics Weigh Against Teva’s Mylan Bid Succeeding

  Will drug company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) succeed in its attempted hostile takeover of rival Mylan (MYL), or will it be Mylan that succeeds in its own hostile takeover More...

Clive Minchom On Monday, June 8th, 2015

Teva Issues New Letter to Mylan NV Confirming Seriousness of Offer to Acquire Mylan

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) issued a new open letter on Monday, signed by both the Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, addressed to Robert More...

Email:

Delivered by FeedBurner